The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?

Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas

(2020) A.J. Schoenfeld et al.   ANNALS OF ONCOLOGY

Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model

(2020) Jing Wu et al.   BIOMEDICINE & PHARMACOTHERAPY

IL-10 suppresses IFN-γ-mediated signaling in lung adenocarcinoma

(2020) Yi Gao et al.   CLINICAL AND EXPERIMENTAL MEDICINE

Impact of DNA damage response and repair (DDR) gene mutations on efficacy of PD-(L)1 immune checkpoint inhibition in non-small cell lung cancer

(2020) Biagio Ricciuti et al.   CLINICAL CANCER RESEARCH

Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC).

(2020) Byoung Chul Cho et al.   JOURNAL OF CLINICAL ONCOLOGY

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer

(2020) Andrea Cavazzoni et al.   Cancers

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC

(2020) Xiaomei Liu et al.   Frontiers in Oncology

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer

(2020) G. Lamberti et al.   ANNALS OF ONCOLOGY

Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication

(2020) Giuseppe Lamberti et al.   Future Oncology

Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial

(2019) Martin Reck et al.   Lancet Respiratory Medicine

Niraparib activates interferon signaling and potentiates anti-PD-1 antibody efficacy in tumor models

(2019) Zebin Wang et al.   Scientific Reports

Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer

(2019) Benjamin P. Levy et al.   EUROPEAN JOURNAL OF CANCER

Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours

(2019) Han Yao et al.   Nature Biomedical Engineering

Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

(2019) Evan Y. Yu et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma

(2019) Peng Song et al.   Interdisciplinary Sciences-Computational Life Sciences

EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

(2019) K Hastings et al.   ANNALS OF ONCOLOGY

Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy

(2019) Heng-Huan Lee et al.   CANCER CELL

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer

(2019) Talia Golan et al.   NEW ENGLAND JOURNAL OF MEDICINE

The TNF Paradox in Cancer Progression and Immunotherapy

(2019) Anne Montfort et al.   Frontiers in Immunology

Recent Findings in the Regulation of Programmed Death Ligand 1 Expression

(2019) Xiangfeng Shen et al.   Frontiers in Immunology

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

(2019) Antonio González-Martín et al.   NEW ENGLAND JOURNAL OF MEDICINE

Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

(2019) Robert L. Coleman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression

(2019) E J Aguilar et al.   ANNALS OF ONCOLOGY

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Mechanisms regulating PD-L1 expression on tumor and immune cells

(2019) Shuming Chen et al.   Journal for ImmunoTherapy of Cancer

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

(2019) Isabelle Ray-Coquard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Circulating microRNAs associated with prolonged overall survival in lung cancer patients treated with nivolumab

(2018) Ann Rita Halvorsen et al.   ACTA ONCOLOGICA

The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1

(2018) Helena J. Janse van Rensburg et al.   CANCER RESEARCH

Synergy between the KEAP1/NRF2 and PI3K Pathways Drives Non-Small-Cell Lung Cancer with an Altered Immune Microenvironment

(2018) Sarah A. Best et al.   Cell Metabolism

MiR-140 Expression Regulates Cell Proliferation and Targets PD-L1 in NSCLC

(2018) Wei-Bin Xie et al.   CELLULAR PHYSIOLOGY AND BIOCHEMISTRY

TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma

(2018) Jerome Biton et al.   CLINICAL CANCER RESEARCH

Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors

(2018) Julius Strauss et al.   CLINICAL CANCER RESEARCH

The Role of mTOR in Neuroendocrine Tumors: Future Cornerstone of a Winning Strategy?

(2018) Giuseppe Lamberti et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The miR-3127-5p/p-STAT3 axis up-regulates PD-L1 inducing chemoresistance in non-small-cell lung cancer

(2018) Dongfang Tang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors

(2018) Jeremy Lewin et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

(2018) Leena Gandhi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells

(2018) Qi Lai et al.   ONCOGENE

miR-142-5p regulates CD4+ T cells in human non-small cell lung cancer through PD-L1 expression via the PTEN pathway

(2018) Jun Wan et al.   ONCOLOGY REPORTS

Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process

(2018) Fang Li et al.   ONCOLOGY REPORTS

Down-regulation of microRNA-135 promotes sensitivity of non-small cell lung cancer to gefitinib by targeting TRIM16

(2018) Ning Wang et al.   ONCOLOGY RESEARCH

STT3-dependent PD-L1 accumulation on cancer stem cells promotes immune evasion

(2018) Jung-Mao Hsu et al.   Nature Communications

STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma

(2018) Ferdinandos Skoulidis et al.   Cancer Discovery

Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion

(2018) Yiting Wang et al.   Frontiers in Pharmacology

Correlation and prognostic significance of PD-L1 and P53 expression in resected primary pulmonary lymphoepithelioma-like carcinoma

(2018) Xiang-Yang Yu et al.   Journal of Thoracic Disease

PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma

(2018) A. Asgarova et al.   OncoImmunology

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

(2018) Aaron M. Goodman et al.   JAMA Oncology

Regulatory mechanisms of PD-L1 expression in cancer cells

(2018) Yongyu Shi   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations

(2018) Maria I. Toki et al.   Journal of Thoracic Oncology

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1

(2018) Jong-Ho Cha et al.   MOLECULAR CELL

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness

(2018) Jianfeng Shen et al.   CANCER RESEARCH

Impact of cytotoxic chemotherapy on PD-L1 expression in patients with non–small cell lung cancer negative for EGFR mutation and ALK fusion

(2018) Hitomi Sakai et al.   LUNG CANCER

Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance

(2018) Yong Liang et al.   Nature Communications

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer

(2018) Junghoon Shin et al.   Cancer Research and Treatment

Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations

(2018) Fatima Karzai et al.   Journal for ImmunoTherapy of Cancer

CD274 (PDL1 ) and JAK2 genomic amplifications in pulmonary squamous-cell and adenocarcinoma patients

(2017) Sergi Clavé et al.   HISTOPATHOLOGY

Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

(2017) Matthew A. Coelho et al.   IMMUNITY

PD-L1 induced by IFN-γ from tumor-associated macrophages via the JAK/STAT3 and PI3K/AKT signaling pathways promoted progression of lung cancer

(2017) Xiaohui Zhang et al.   International Journal of Clinical Oncology

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

(2017) Jung-Min Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3–PD-L1 ≥50% Expression in Lung Adenocarcinoma

(2017) Deepa Rangachari et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells

(2017) Kenichi Suda et al.   LUNG CANCER

PIK3CA mutations as prognostic factor in squamous cell lung carcinoma

(2017) Marc McGowan et al.   LUNG CANCER

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

(2017) Mark Robson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells

(2017) J Feng et al.   ONCOGENE

BIN1 reverses PD-L1-mediated immune escape by inactivating the c-MYC and EGFR/MAPK signaling pathways in non-small cell lung cancer

(2017) J Wang et al.   ONCOGENE

MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer

(2017) A Bouillez et al.   ONCOGENE

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

(2017) Anna Minchom et al.   PLoS One

DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells

(2017) Hiro Sato et al.   Nature Communications

Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non–Small Cell Lung Cancer

(2017) Dennis O. Adeegbe et al.   Cancer Discovery

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

(2017) Johann de Bono et al.   Cancer Discovery

DNA Damage and Repair Biomarkers of Immunotherapy Response

(2017) Kent W. Mouw et al.   Cancer Discovery

TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)

(2017) Xiaobo Cao et al.   Oncotarget

Tumor-associated macrophages promote tumor metastasis via the TGF-β/SOX9 axis in non-small cell lung cancer

(2017) Shuai Zhang et al.   Oncotarget

YAP regulates PD-L1 expression in human NSCLC cells

(2017) Jinbai Miao et al.   Oncotarget

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer

(2017) Emilie Evanno et al.   Clinical Epigenetics

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape

(2017) Takuro Noguchi et al.   Cancer Immunology Research

Identifying Regulatory Posttranslational Modifications of PD-L1: A Focus on Monoubiquitinaton

(2017) Henrick Horita et al.   NEOPLASIA

A novel bifunctional anti-PD-L1/TGF-β Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells

(2017) Justin M. David et al.   OncoImmunology

EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer

(2017) Zhong-Yi Dong et al.   OncoImmunology

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy

(2017) Hélène Roussel et al.   OncoImmunology

A Novel Link between Inflammation and Cancer

(2016) Yenkel Grinberg-Bleyer et al.   CANCER CELL

YAP/TAZ at the Roots of Cancer

(2016) Francesca Zanconato et al.   CANCER CELL

Deubiquitination and Stabilization of PD-L1 by CSN5

(2016) Seung-Oe Lim et al.   CANCER CELL

STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment

(2016) S. Koyama et al.   CANCER RESEARCH

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

(2016) Zhong-Yi Dong et al.   CLINICAL CANCER RESEARCH

EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

(2016) J. F. Gainor et al.   CLINICAL CANCER RESEARCH

Pan-cancer analysis of copy number changes in programmed death-ligand 1 (PD-L1, CD274) - associations with gene expression, mutational load, and survival

(2016) Jan Budczies et al.   GENES CHROMOSOMES & CANCER

The EGFR pathway is involved in the regulation of PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in EGFR-mutated non-small cell lung cancer

(2016) Nan Zhang et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

PD-L1 Is Upregulated by Simultaneous Amplification of the PD-L1 and JAK2 Genes in Non–Small Cell Lung Cancer

(2016) Seiichi Ikeda et al.   Journal of Thoracic Oncology

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

(2016) Roy S Herbst et al.   LANCET

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

(2016) Yoon Jin Cha et al.   LUNG CANCER

Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers

(2016) Keisuke Kataoka et al.   NATURE

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity

(2016) Chia-Wei Li et al.   Nature Communications

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

(2016) Casey Ager et al.   Journal for ImmunoTherapy of Cancer

Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy

(2016) Sadakatsu Ikeda et al.   npj Genomic Medicine

RAS–Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers

(2016) Hidetoshi Sumimoto et al.   PLoS One

EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB

(2015) Kailong Lin et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer

(2015) Kristin J. Lastwika et al.   CANCER RESEARCH

Induction of PD-L1 Expression by the EML4-ALK Oncoprotein and Downstream Signaling Pathways in Non-Small Cell Lung Cancer

(2015) K. Ota et al.   CLINICAL CANCER RESEARCH

VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors

(2015) Thibault Voron et al.   JOURNAL OF EXPERIMENTAL MEDICINE

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer

(2015) Johan F. Vansteenkiste et al.   Journal of Thoracic Oncology

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

(2015) Nan Chen et al.   Journal of Thoracic Oncology

The Clinical Relevance of the miR-197/CKS1B/STAT3-mediated PD-L1 Network in Chemoresistant Non-small-cell Lung Cancer

(2015) Yu Fujita et al.   MOLECULAR THERAPY

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

PDL1 Regulation by p53 via miR-34

(2015) Maria Angelica Cortez et al.   JNCI-Journal of the National Cancer Institute

EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3

(2015) Jaemoon Koh et al.   OncoImmunology

Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy

(2015) Bingbing Dai et al.   PLoS One

Alterations of immune response of non-small cell lung cancer with Azacytidine

(2015) John Wrangle et al.   Oncotarget

Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer

(2014) K. Azuma et al.   ANNALS OF ONCOLOGY

Loss of Lkb1 and Pten Leads to Lung Squamous Cell Carcinoma with Elevated PD-L1 Expression

(2014) Chunxiao Xu et al.   CANCER CELL

Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in mice

(2014) Liufu Deng et al.   JOURNAL OF CLINICAL INVESTIGATION

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

(2014) Muhammad Zaeem Noman et al.   JOURNAL OF EXPERIMENTAL MEDICINE

A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)

(2014) Yuankai Shi et al.   Journal of Thoracic Oncology

Ubiquitination involved enzymes and cancer

(2014) Mei-juan Zhou et al.   MEDICAL ONCOLOGY

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression

(2014) Limo Chen et al.   Nature Communications

An Intact Immune System Is Required for the Anticancer Activities of Histone Deacetylase Inhibitors

(2013) A. C. West et al.   CANCER RESEARCH

IFN-γ-Stimulated Neutrophils Suppress Lymphocyte Proliferation through Expression of PD-L1

(2013) Stan de Kleijn et al.   PLoS One

Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors

(2013) E. A. Akbay et al.   Cancer Discovery

Comprehensive identification of mutational cancer driver genes across 12 tumor types

(2013) David Tamborero et al.   Scientific Reports

Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers

(2012) S. Dogan et al.   CLINICAL CANCER RESEARCH

Protein monoubiquitination and polyubiquitination generate structural diversity to control distinct biological processes

(2011) Martin Sadowski et al.   IUBMB LIFE

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

MicroRNAs: Target Recognition and Regulatory Functions

(2009) David P. Bartel   CELL

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE